C3BS-CQR-1
/ Celyad Oncology
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
January 13, 2013
CHART-1: Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.
(clinicaltrials.gov)
- P3 | N=240 | Recruiting | Sponsor: Cardio3 BioSciences
New P3 trial • Cardiovascular • Heart Failure
June 03, 2018
CHART-1: Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.
(clinicaltrials.gov)
- P3 | N=315 | Completed | Sponsor: Celyad (formerly named Cardio3 BioSciences) | Trial primary completion date: Apr 2016 ➔ Aug 2017
Trial primary completion date • Cardiovascular • Heart Failure
November 09, 2017
CHART-1: Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.
(clinicaltrials.gov)
- P3 | N=315 | Completed | Sponsor: Celyad (formerly named Cardio3 BioSciences) | Active, not recruiting ➔ Completed | N=240 ➔ 315
Enrollment change • Trial completion • Cardiovascular • Heart Failure
May 19, 2015
CHART-1: Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.
(clinicaltrials.gov)
- P3 | N=240 | Active, not recruiting | Sponsor: Celyad (formerly named Cardio3 BioSciences) | Recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2014 ➔ Apr 2016
Enrollment closed • Trial primary completion date • Cardiovascular • Heart Failure
1 to 4
Of
4
Go to page
1